April 13, 2018
The Establishment and Characterization of PDX Models
Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo oncology studies than were previously accessible to researchers. Here’s how PDX models differ from traditional xenografts, and how we develop and characterize them for oncology and immuno-oncology studies.
LEARN MORE
April 5, 2018
The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays
Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often used to reduce system ...
LEARN MORE
March 22, 2018
Are There Are Five Types of Diabetes?
New research suggests that there are five types of diabetes, rather than simply Type 1 or Type 2. Understanding ...
LEARN MORE
March 19, 2018
Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology
Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to cancer, with antibodies ...
LEARN MORE
March 13, 2018
ICOS: Immunostimulatory or Immunosuppressive Target?
The rise of immunotherapy has brought many new targets to the forefront of oncology drug development. One promising new ...
LEARN MORE
March 7, 2018
New Technique Opens Novel Approaches to Insulin Resistance
A newly-described technique could open multiple lines of investigation into the pathophysiology and treatment of ...
LEARN MORE
March 1, 2018
Using T Cells in Immuno-Oncology
Immuno-oncology drug development challenges researchers to model the interaction between novel immunotherapy agents, functional T cells, and in vivo models of cancer. In this introduction to T cells and immunotherapy studies, we’ll explore the function and analysis of T cells in preclinical drug development.
LEARN MORE
February 27, 2018
CAR-T Cell Therapy: Use Earlier for Better Results
CAR-T cell therapies are still in their infancy as clinical oncology treatments, with the first agent approved just 6 ...
LEARN MORE
February 22, 2018
Tumor Infiltrating Lymphocytes: Conflicting Approaches in Immuno-Oncology
Today’s new frontier in cancer treatment is in fact a very, very old frontier indeed: tumor infiltrating lymphocytes ...
LEARN MORE
February 20, 2018
How to Assess CAR-T Cell Therapies Preclinically
Chimeric antigen receptor (CAR)-T cell therapies are a new and novel immuno-oncology treatment modality, only recently ...
LEARN MORE
February 16, 2018
3 Key Uses for Humanized Mouse Models
We’ve been focusing on humanized mouse models recently on our blog, from evolution of immunodeficient host mice through to the development of derivative hPBMC and hCD34+ HSC humanized mice. This post now takes a look at how you can combine humanized mice with human tumors for three key uses in assessing human-specific immunotherapeutics.
LEARN MORE
February 9, 2018
X Chromosome Inactivation: New Hypothesis for Lupus Gender Disparity
It’s widely accepted that lupus occurs more often in women than men, with many studies over the years trying to ...
LEARN MORE
January 30, 2018
Humanized Mouse Model Head to Head: hPBMC vs hCD34+
The future of cancer treatment is often considered to be combination regimens (dual immunotherapeutics or ...
LEARN MORE
January 26, 2018
Comparison Guide: huNOG® & huNSG™ Humanized Models
Previously our blog posts have reviewed humanized mice, looking at hPBMC vs hCD34+ models, how they differ, and how to ...
LEARN MORE
January 5, 2018
2018 Technology Advances – Applying Next Generation Sequencing to Single Cell Analysis
It is an axiom in biology that expression of genotype determines phenotype. This means, for the large part, that the ...
LEARN MORE
